Mark A. Kronenfeld
Insider
First SEC filing: Sept. 13, 2013 · Latest: Sept. 13, 2013
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net: $0
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| June 11, 2025 | PCRX | A | 6,163 | · | · | 31,065 Direct | +24.75% | Acquired | (price as of 2026-10-05) |
| June 11, 2025 | PCRX | A | 9,999 | · | · | 34,901 Direct | +40.15% | Acquired | (price as of 2026-10-05) |
| June 11, 2025 | PCRX | A | 11,279 | · | · | 11,279 Direct | · | Acquired | (price as of 2026-10-05) |
| June 12, 2024 | PCRX | A | 5,230 | · | · | 24,902 Direct | +26.59% | Acquired | (price as of 2026-10-05) |
| June 12, 2024 | PCRX | A | 12,179 | · | · | 12,179 Direct | · | Acquired | (price as of 2026-10-05) |
| June 14, 2023 | PCRX | A | 12,925 | · | · | 12,925 Direct | · | Acquired | (price as of 2026-10-05) |
| June 14, 2023 | PCRX | A | 1,775 | · | · | 19,672 Direct | +9.92% | Acquired | (price as of 2026-10-05) |
| June 8, 2023 | PCRX | M 10b5-1 | 15,000 | · | · | 0 Direct | -100.00% | Disposed | (price as of 2026-10-05) |
| June 8, 2023 | PCRX | S 10b5-1 | 15,000 | $37.04 | $555,600 | 17,897 Direct | -45.60% | Disposed | -32.4% (price as of 2026-10-05) |
| June 8, 2023 | PCRX | M 10b5-1 | 15,000 | $29.90 | $448,500 | 32,897 Direct | +83.81% | Acquired | -16.2% (price as of 2026-10-05) |
| June 8, 2022 | PCRX | A | 8,225 | · | · | 8,225 Direct | · | Acquired | (price as of 2026-10-05) |
| June 8, 2022 | PCRX | A | 1,160 | · | · | 17,897 Direct | +6.93% | Acquired | (price as of 2026-10-05) |
| June 9, 2021 | PCRX | A | 1,066 | · | · | 16,737 Direct | +6.80% | Acquired | (price as of 2026-10-05) |
| June 9, 2021 | PCRX | A | 7,626 | · | · | 7,626 Direct | · | Acquired | (price as of 2026-10-05) |
| June 9, 2020 | PCRX | A | 8,027 | · | · | 8,027 Direct | · | Acquired | (price as of 2026-10-05) |
| June 9, 2020 | PCRX | A | 1,260 | · | · | 15,671 Direct | +8.74% | Acquired | (price as of 2026-10-05) |
| June 5, 2019 | PCRX | A | 8,437 | · | · | 8,437 Direct | · | Acquired | (price as of 2026-10-05) |
| June 5, 2019 | PCRX | A | 4,134 | · | · | 14,411 Direct | +40.23% | Acquired | (price as of 2026-10-05) |
| March 6, 2019 | PCRX | P | 1,000 | $39.14 | $39,140 | 10,277 Direct | +10.78% | Acquired | -36.0% (price as of 2026-10-05) |
| March 6, 2019 | PCRX | P | 700 | $38.72 | $27,104 | 9,277 Direct | +8.16% | Acquired | -35.3% (price as of 2026-10-05) |
| Aug. 28, 2018 | PCRX | P | 1,000 | $44.61 | $44,610 | 8,577 Direct | +13.20% | Acquired | -43.8% (price as of 2026-10-05) |
| June 13, 2018 | PCRX | A | 4,693 | · | · | 4,693 Direct | · | Acquired | (price as of 2026-10-05) |
| June 13, 2018 | PCRX | A | 782 | · | · | 7,577 Direct | +11.51% | Acquired | (price as of 2026-10-05) |
| Nov. 10, 2017 | PCRX | P | 1,000 | $41.60 | $41,600 | 6,795 Direct | +17.26% | Acquired | -39.8% (price as of 2026-10-05) |
| June 14, 2017 | PCRX | A | 2,714 | · | · | 2,714 Direct | · | Acquired | (price as of 2026-10-05) |
| June 14, 2017 | PCRX | A | 1,357 | · | · | 5,795 Direct | +30.58% | Acquired | (price as of 2026-10-05) |
| June 15, 2016 | PCRX | A | 2,975 | · | · | 2,975 Direct | · | Acquired | (price as of 2026-10-05) |
| June 15, 2016 | PCRX | A | 1,488 | · | · | 4,438 Direct | +50.44% | Acquired | (price as of 2026-10-05) |
| June 6, 2016 | PCRX | S 10b5-1 | 900 | $46.95 | $42,255 | 2,950 Direct | -23.38% | Disposed | -46.6% (price as of 2026-10-05) |
| June 3, 2015 | PCRX | A | 4,000 | · | · | 4,000 Direct | · | Acquired | (price as of 2026-10-05) |
| June 3, 2015 | PCRX | A | 2,000 | · | · | 3,850 Direct | +108.11% | Acquired | (price as of 2026-10-05) |
| Nov. 3, 2014 | PCRX | P | 850 | $90.48 | $76,908 | 1,850 Direct | +85.00% | Acquired | -72.3% (price as of 2026-10-05) |
| June 3, 2014 | PCRX | A | 8,000 | · | · | 8,000 Direct | · | Acquired | (price as of 2026-10-05) |
| Sept. 11, 2013 | PCRX | P | 1,000 | $37.01 | $37,010 | 1,000 Direct | · | Acquired | -32.3% (price as of 2026-10-05) |
| June 12, 2013 | PCRX | A | 15,000 | · | · | 15,000 Direct | · | Acquired | (price as of 2026-10-05) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| June 11, 2025 | PCRX | Stock Option (Right to Buy) | Common Stock | $24.34 | June 11, 2035 | 11,279 | Acquired |
| June 12, 2024 | PCRX | Stock Option (Right to Buy) | Common Stock | $28.68 | June 12, 2034 | 12,179 | Acquired |
| June 14, 2023 | PCRX | Stock Option (Right to Buy) | Common Stock | $38.74 | June 14, 2033 | 12,925 | Acquired |
| June 8, 2023 | PCRX | Stock Option (Right to Buy) | Common Stock | $29.90 | June 11, 2023 | 15,000 | Disposed |
| June 8, 2022 | PCRX | Stock Option (Right to Buy) | Common Stock | $59.39 | June 8, 2032 | 8,225 | Acquired |
| June 9, 2021 | PCRX | Stock Option (Right to Buy) | Common Stock | $60.96 | June 9, 2031 | 7,626 | Acquired |
| June 9, 2020 | PCRX | Stock Option (Right to Buy) | Common Stock | $47.65 | June 9, 2030 | 8,027 | Acquired |
| June 5, 2019 | PCRX | Stock Option (Right to Buy) | Common Stock | $43.54 | June 5, 2029 | 8,437 | Acquired |
| June 13, 2018 | PCRX | Stock Option (Right to Buy) | Common Stock | $38.35 | June 13, 2028 | 4,693 | Acquired |
| June 14, 2017 | PCRX | Stock Option (Right to Buy) | Common Stock | $44.20 | June 14, 2027 | 2,714 | Acquired |
| June 15, 2016 | PCRX | Stock Option (Right to Buy) | Common Stock | $40.34 | June 15, 2026 | 2,975 | Acquired |
| June 3, 2015 | PCRX | Stock Option (Right to Buy) | Common Stock | $79.43 | June 3, 2025 | 4,000 | Acquired |
| June 3, 2014 | PCRX | Stock Option (Right to Buy) | Common Stock | $81.00 | June 3, 2024 | 8,000 | Acquired |
| June 12, 2013 | PCRX | Stock Option (Right to Buy) | Common Stock | $29.20 | June 11, 2023 | 15,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).